Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.580
-0.060 (-2.27%)
At close: Aug 28, 2026, 4:00 PM EDT
2.680
+0.100 (3.88%)
After-hours: Aug 28, 2026, 7:52 PM EDT
Atossa Therapeutics Stock Forecast
ATOS's stock price has decreased by -77.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 analysts polled by S&P Global, Atossa Therapeutics stock has a consensus rating of "Buy" and an average price target of $18.67. The average 1-year stock price forecast is 623.64% higher than the current stock price, while the lowest is $10 (+287.60%) and the highest is $24 (+830.23%).
Price Target: $18.67 (+623.64%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Atossa Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +287.60% | Aug 11, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Buy Initiates $12 | Buy | Initiates | $12 | +365.12% | Jul 7, 2026 |
| Ascendiant | Ascendiant | Buy Maintains $24 | Buy | Maintains | $24 | +830.23% | Apr 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.40
from -4.04
EPS Next Year
-4.38
from -4.40
EPS and Forward PE are based on non-GAAP adjusted numbers.